Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants (GENBPD)

This study is enrolling participants by invitation only.
Information provided by:
Centre Hospitalier Intercommunal Creteil Identifier:
First received: May 19, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted

Despite considerable obstetric and neonatal advances in the care of very low birth weight (VLBW) neonates, bronchopulmonary dysplasia (BPD) continues to occur among 20 to 40% of surviving infants, and new ways for combatting this disease must be found. BPD appears to result from arrested lung development, but its etiology has not yet been fully established. Besides the role of the exposure of the immature lung to injurious factors in the development of BPD, a genetic susceptibility for BPD in preterm infants was recently evidenced. Taking advantage of new genomic technologies, the objective of the investigators' project is to identify predisposing human genetic variants through:

  1. a genome-wide association (GWA) study in VLBW neonates,
  2. a candidate-gene association study, including selection of single nucleotide polymorphisms (SNPs) found in (a) and
  3. functional studies of any SNP found to be convincingly associated with BPD in (a) and (b).

Bronchopulmonary Dysplasia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Polymorphisms of Genes Controlling Alveolar Development and Risk of Bronchopulmonary Dysplasia

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Intercommunal Creteil:

Primary Outcome Measures:
  • bronchopulmonary dysplasia [ Time Frame: 36 weeks of postconceptional age ] [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: May 2009
premature neonates
gestational age less than 28 weeks


Ages Eligible for Study:   up to 8 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Premature neonates

Inclusion Criteria:

  • Gestational age < 28 weeks
  • Inborn birth
  • Prophylactic administration of surfactant in the delivery room
  • Written informed consent obtained from parents

Exclusion Criteria:

  • Gestational age of 28 weeks or more
  • Outborn birth
  • No prophylactic administration of surfactant in the delivery room
  • Congenital malformation
  • Absence of written informed consent obtained from parents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00904774

Centre Hospitalier Intercommunal
Creteil, France, 94000
Sponsors and Collaborators
Centre Hospitalier Intercommunal Creteil
  More Information

Additional Information:
Responsible Party: Delacourt, Christophe, MD, PhD, INSERM U955 Identifier: NCT00904774     History of Changes
Other Study ID Numbers: AOR 07 018 
Study First Received: May 19, 2009
Last Updated: May 19, 2009
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Centre Hospitalier Intercommunal Creteil:
bronchopulmonary dysplasia
lung development

Additional relevant MeSH terms:
Bronchopulmonary Dysplasia
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Diseases
Lung Injury
Respiratory Tract Diseases
Ventilator-Induced Lung Injury processed this record on May 26, 2016